Price
CHART BY
Frequently asked questions
What is the Earnings Per Share (EPS) for Metsera, Inc.?
Metsera, Inc.'s Earnings Per Share (EPS) over the trailing twelve months (TTM) is -2.994. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Metsera, Inc.'s stock?
Currently, 1 analysts cover Metsera, Inc.'s stock, with a consensus target price of $57.00. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Metsera, Inc.?
Metsera, Inc.'s Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$265.12M. EBITDA measures the company's overall financial performance.
How many employees does Metsera, Inc. have, and what sector and industry does it belong to?
Metsera, Inc. employs approximately 81 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
Financials
- EPS (TTM)
- -2.994
- EBITDA (TTM)
- -$265.12M
Pricing
- 52W span
- 12.3183.67
Analyst Ratings
The price target is $57.00 and the stock is covered by 1 analysts.
Buy
0
Hold
1
Sell
0
Information
Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.
- Employees
- 81
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- MTSR
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet